43 results
8-K
EX-99.1
NDRA
ENDRA Life Sciences Inc
6 Jun 24
ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering
8:00am
assessment of fatty tissue in the liver. Steatotic liver disease (SLD, formerly known as NAFLD-NASH) is a chronic liver disease spectrum that affects over
8-K
EX-99.1
NDRA
ENDRA Life Sciences Inc
20 May 24
ENDRA Provides Update Following In-person Meeting with FDA
8:05am
of fatty tissue in the liver. Steatotic liver disease (SLD, formerly known as NAFLD-NASH) is a chronic liver disease spectrum that affects over two
8-K
EX-99.1
NDRA
ENDRA Life Sciences Inc
14 May 24
ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update
4:17pm
of fat in the liver as a means to assess and monitor steatotic liver disease (SLD) (formerly known as NAFLD-NASH), a chronic liver disease spectrum
8-K
EX-99.1
NDRA
ENDRA Life Sciences Inc
28 Mar 24
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:10pm
to assess and monitor steatotic liver disease (SLD) (formerly known as NAFLD-NASH), a chronic liver disease spectrum that affects over two billion people
8-K
EX-99.1
t8q293n90j
14 Nov 23
ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
4:02pm
8-K
EX-99.1
qhe031f8wlga l9dhu
14 Aug 23
ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update
4:13pm
8-K
EX-99.2
2dj2robvrzgl3bbe qz
14 Aug 23
ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update
4:13pm
8-K
EX-99.1
u7jbqrbevwuojq1j
6 Jul 23
ENDRA Life Sciences Announces Adjournment of
5:25pm
DEFA14A
EX-99.1
s9vbzr psbfkl6qs
6 Jul 23
Additional proxy soliciting materials
5:25pm
8-K
EX-99.1
2tfx0 f7i
15 May 23
ENDRA Life Sciences Reports First Quarter 2023 Financial Results and Provides a Business Update
12:00am
8-K
EX-99.2
08vjw
2 May 23
ENDRA Life Sciences Announces Pricing of Upsized $4.5 Million Public Offering
4:16pm
8-K
EX-99.1
g3uct4ucywk
2 May 23
ENDRA Life Sciences Announces Pricing of Upsized $4.5 Million Public Offering
4:16pm
8-K
EX-99.1
vqq4es ora5
14 Nov 22
ENDRA Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
4:32pm
8-K
EX-99.1
3crlt1frzr
15 Aug 22
ENDRA Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
5:17pm
8-K
EX-99.1
t43tgugp
12 May 22
ENDRA Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
4:06pm
8-K
EX-99.1
sund0su8vnbieek
21 Apr 22
Regulation FD Disclosure
8:08am
8-K
EX-99.1
qy4xz8s796qq6
30 Mar 22
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
4:11pm
8-K
EX-99.1
17v ivakff82f26bm8i
10 Feb 22
ENDRA Life Sciences Provides Update on U.S. Regulatory Strategy for its TAEUS® System
8:00am